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Abstract
Background: Several single nucleotide polymorphisms (SNPs) in lipid transport genes have been shown to be
associated with premature coronary artery disease (PCAD). The scavenger receptor BI (SCARB1) is a key component
of the reverse cholesterol transport and lipid metabolism. We aimed to examine the relationship between the
rs5888 SNP within SCARB1and the risk of angiographically determined PCAD.
Methods: We used an age cut-off of 55 years for women and 45 years for men to define PCAD. Five-hundred and
five patients with newly diagnosed angiographically documented PCAD (≥50 % luminal stenosis of any coronary
vessel) as case group compared with 546 controls (subjects with no luminal stenosis at coronary arteries). The
severity of CAD was determined by vessel score as well as Gensini score. A real-time polymerase chain reaction
(PCR) and High Resolution Melting (HRM) analysis was used to distinguish between genotypes.
Results: T allele as compared to C allele was associated with increased odds of PCAD in total population (adjusted
OR = 1.3, 95 % CI = 1.0 to 1.5; p = 0.020), and in women (adjusted OR = 1.3, 95 % CI = 1.0 to 1.8; p = 0.037), but not in
men (adjusted OR = 1.2, 95 % CI = 0.9 to 1.5; p = 0.311). There was also no significant association between the
examined polymorphism and the severity of CAD in whole or in men or women subgroups.
Conclusions: Our findings suggest that the SNP (rs5888) within SCARB1 is independently associated with PCAD in
a sex-dependent manner.
Keywords: Coronary artery disease, Premature atherosclerosis, Coronary angiography, Scavenger receptor class B
type I, rs5888 polymorphism
Background
The occurrence of coronary artery disease (CAD) in
younger subjects, although infrequent, causes devastat-
ing effect on the more active lifestyle of this group of pa-
tients and may result in premature death [1]. Patients
with premature CAD (PCAD), defined as the presence
of coronary artery atherosclerotic lesion in men ≤45 year
and women ≤55 years, have different risk factor profiles,
clinical presentations, and prognoses than older patients
[2]. Even though the identification of risk factors for
PCAD is of essential importance for the understanding of
its origins and for establishing preventive strategies, the
mechanisms and predictors of PCAD are still not com-
pletely understood [3]. Risk factors for CAD are both en-
vironmental and genetic. In patients with PCAD, the role
of genetic risk factors is expected to be more important
than that of environmental factors [4]. Over the past re-
cent years, several single nucleotide polymorphisms
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(SNPs) in lipid transport genes have been shown to be as-
sociated with PCAD [5–9].
Scavenger receptor class B type1 (SCARB1, also called
SR-BI) is a multiligand cell surface receptor expresses
both in macrophages and in the liver, indicating a major
role for in the clearance of excess cholesterol from the
body [10]. This membrane protein facilitates the uptake
of cholesteryl esters from high-density lipoprotein chol-
esterol (HDL-C) and drives cholesterol from tissues to
the liver in the various stages of reverse cholesterol
transport pathway. This makes SCARB1 gene as an at-
tractive candidate gene for CAD. The SCARB1 gene is
located on 12q24.31 encompassing 13 exons and spans
approximately 75 kb. Various SCARB1 polymorphisms
in humans have been shown to be associated with al-
tered serum lipid profile but their influence on CAD de-
velopment or severity is still unclear [11]. One exonic
SNP (rs5888) within SCARB1, has been linked to lower
SR-BI protein expression and function [12]. This SNP is
a “C” to “T” substitution at cDNA position 1050 base
position on exon 8, and a coding-synonymous poly-
morphism (A350A) which was initially found by Acton
et al. [13]. Several studies on rs5888 polymorphism and
the risk of CAD have been previously published with
contradictory results [14–18]. There is even controversy
about which allele confers increased risk. Wu et al. [14]
found that the individuals with TT genotype were associ-
ated with increased CAD risk, whereas others reported
that the T allele or the T allele carrier was associated
with decreased risk of CAD [15–18]. Moreover, they
have investigated this association amongst general CAD
populations and there is no study, that we are aware of,
studying this association in PCAD patients. Thus, the
aim of the present study was to examine the relation of
rs5888 SNP with the presence and severity of angio-
graphically determined PCAD in an Iranian coronary
population.
Methods
Study participants and coronary angiograms
A prior study has used an age cut-off of 55 years for
women and 45 years for men to define “young” patients
with CAD [2]. To define PCAD, the same age definition
was used in this study. This age- and sex-matched case–
control study was conducted on 560 patients with newly
diagnosed angiographically documented PCAD and an
equal number of controls with normal coronary arteries.
Cases were selected consecutively from those who, be-
tween August 2009 and May 2011, underwent coronary
angiography at the catheterization laboratory of our cen-
ter because of symptoms related to CAD or the results
of non-invasive tests. Unrelated matched controls were
selected from a pool of 1547 young patients (419 men
and 1128 women) who, between June 2004 and July
2011, consecutively admitted for elective coronary angi-
ography at our hospital. Cases and controls were
matched for age within two years. Exclusion criteria in-
cluded previous history of acute myocardial infarction
(MI), stent implantation, cardiopulmonary resuscitation
(CPR), and coronary artery bypass graft surgery. Also,
patients on lipid-lowering drugs and those with minimal
CAD (coronary lesions with less than 50 % luminal sten-
osis) were excluded. The study protocol was approved
by the local ethical committee. Written informed con-
sent was obtained from all patients in agreement with
the Declaration of Helsinki for research involving human
subjects explicitly provided permission for DNA analyses
and gathering the relevant clinical data.
Coronary angiographies were performed by the percu-
taneous femoral approach using standard techniques.
The presence and severity of CAD was determined by
clinical vessel score. All cases showed the evidence of
atherosclerosis i.e., ≥ 50 % luminal stenosis in at least
one coronary artery or major branch segment in their epi-
cardial coronary tree. Controls had no luminal stenosis at
coronary angiograph. The severity of CAD was also deter-
mined by a semi-quantitative scoring system (Gensini
score) which has been previously described [19]. Two car-
diologists, blind to the study results, interpreted all angio-
grams. Definitions for analyzed risk factors of CAD
including, body mass index (BMI), dyslipidemia, hyperten-
sion, cigarette smoking, opium addiction, and diabetes
have been reported elsewhere [20, 21].
Sample collection and DNA extraction
From June 2004 to July 2011, for the purpose of creating
a “DNA-bank of patients with PCAD and controls”, all
young patients (age ≤45 years for men, and age ≤55 years
for women at the disease onset) admitted for elective
coronary angiography at our center were asked to pro-
vide a sample of whole blood for DNA extraction Per-
ipheral venous blood samples were collected from an
antecubital vein after 12 h overnight fasting of partici-
pants. Upon arrival at the laboratory, each participant
provided about 15-mL venous blood sample. 5 mL blood
was collected in plain tubes and used for biochemical as-
says immediately; the rest of the sample (10 ml) placed
in ethylenediamine tetraacetic acid (EDTA)-containing
tubes and stored deep-frozen until later use. Genomic
DNA was extracted from leukocytes using the buffy coat
of the stored EDTA whole blood samples. DNA extrac-
tion carried out using the standard ‘salting out’ method.
DNA quantity was evaluated by calculating absorbance
at λ = 260 nm, and the quality was assessed by a ratio of
λ = 260/280 nm being close to 1.8. The purified DNA
was stored in Tris-EDTA buffer (pH 8.0) at –70 °C until
further analysis.
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PCR amplification and genotype analysis
Real-time polymerase chain reaction (PCR) and High-
Resolution Melting (HRM) analysis was applied for the
genotype analysis using Corbett Rotor-Gene 6000 real-
time rotary analyzer (Corbett Life Science Pty. Ltd.,
Mortlake, NSW, Australia). One set of primers based
on common HRM specifications was designed using
Beacon Designer software version 7.0 (Premier Biosoft
International, Palo Alto, CA, USA) and synthesized
by Bioneer Inc. (Daejeon, Korea). The forward primer
was 5′- CTTGTTTCTCTCCCATCCTCA -3′ and the
reverse was 5′- GAGTGTGCCTCCTGGTTAG -3′.
The final reaction mixture contained Type-it HRM
Master Mix (QIAGEN NV, Venlo, Netherlands) with
intercalating DNA-binding Evagreen dye (Biotium,
Inc. Hayward, CA, USA), DNA polymerase (5U/ml),
primer mix (0.4 μM of each primer), genomic DNA
(50 ng), and RNase Free Water (QIAGEN NV) in a
total volume of 20 μl. The PCR cycling conditions
consisted of an initial denaturation at 95 °C for
15 min, followed by 37 cycles of denaturation (96 °C
for 20 s), primer annealing (62 °C for 20 s), and ex-
tension (72 °C for 15 s). One positive control for each
genotype (CC, CT, and TT) and one appropriate
negative control were included in each run. The positive
controls were verified by using the PCR with restriction
fragment length polymorphism (RFLP) technique as de-
scribed previously with minor modification [22]. The ge-
notypes were separated by electrophoresis on 2 % agarose
gel stained with ethidium bromide (Fig. 1) and also con-
firmed by direct DNA sequence analysis.
Following the PCR amplification steps, melt curves for
the products were generated by heating in 0.1 °C incre-
ments at a rate of 2 s per each step over the temperature
range from 65 to 95 °C. The HRM data were analyzed
using the Rotor-Gene Q software package supplied with
the instrument. Sequence variations were distinguished
from wild-type samples by the different shapes of nor-
malized and temperature-shifted melting curves. In sam-
ples which failed to give an interpretable HRM pattern
(10 %), the PCR-RFLP method was used for genotyping
and reconfirmed by direct sequencing in 15 samples.
Statistical analysis
Continuous variables are reported as “mean ± standard
deviation” and categorical variables as “numbers and
percentage”. Variables were tested for normality by visu-
ally inspection of box-plots and by using Kolmogorov–
Smirnov normality test. Gensini score, which was
skewed, presented as median and inter-quartile range
(25th to 75th percentiles). The case and control groups
were compared using the independent two-sample Stu-
dent t-test (or Mann-Whitney U-test if required) for the
continuous variables and the chi-square test (or the
Fisher exact test, as appropriate) for the categorical vari-
ables. Due to the highly skewed distribution of Gensini
scores, to compare Gensini score among rs5888 geno-
types, the Kruskal-Wallis analysis was chosen and subjects
with normal coronary arteries (Gensini score = 0, n = 546)
were excluded to ensure any observed effect on graded se-
verity was not being driven by those without any CAD in
whom risk allele frequency is expected to be significantly
lower.
Logistic regression model was constructed to test the
independent relationship between the rs5888 variants
and the presence of CAD with the SNP coded as 0, 1, or
2 based on the number of risk (T) alleles. Analyses were
repeated after adjusting for diabetes mellitus, cigarette
smoking, opium addiction, hypertension, and family his-
tory of CAD as well as serum HDL-C, triglyceride, and
LDL-C in an established multivariable model. Odds ratio
(OR) and 95 % confidence intervals (CI) were calculated
in all patients and in males and females separately.
Moreover, a linear multiple regression analysis with the
presence of CAD severity (Gensini score as a continuous
variable) as the dependent variable, was performed. The
following were tested as potential risk factors: diabetes
mellitus, cigarette smoking, opium addiction, hyperten-
sion, and family history of CAD as well as BMI and serum
levels of HDL-C, triglyceride, and LDL-C. Non-normal
variables, such as Gensini scores, were natural log-
transformed before entering the model. Additionally, a
multiple ordinal logistic regression model, with number of
Fig. 1 Agarose gel electrophoresis for the rs5888 polymorphism of
scavenger receptor class B type 1 (SCARB1) gene. The 218-bp PCR
product of SCARB1 rs5888 (C > T) was digested by Hin1I (BsaHI)
restriction enzyme. The C allele codes for the presence of the Hin1I
site and the T allele codes its absence. The wild-type CC variant
produced two fragments with 187 bp and 31 bp while heterozygote
CT produced 3 fragments of 218 bp, 187 bp, and 31 bp. The mutated
homozygous variant TT produced one fragment of 218 bp. The 31 bp
fragment was not visible in the gel due to its fast migration speed. M,
50 bp marker ladder; Lanes 6 and 10, CC genotype; Lanes 2, 5, 7, 8, 9,
and 12, CT genotype; Lanes 1, 3, 4, and 11, TT genotype
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diseased vessels as the dependent variable, was established
with adjusting for aforementioned potential risk factors. A
generalized linear model (GLM) was used to analyze the
association between the genotypes and lipid profile ad-
justed for age, sex, BMI, and cigarette smoking. A p
value ≤ 0.05 was considered statistically significant. All
Statistical analyses were done by PASW Statistics for
Windows, Version 18.0. (Chicago: SPSS Inc.).
Results
Sixty-nine patients (55 cases and 14 controls) were ex-
cluded due to missing data or genotyping failure, result-
ing in 1051 patients entered in the statistical analyses
including 505 cases, and 546 controls. The mean age of
the study participants was 46 ± 6 years and 45.4 % were
men. Baseline characteristics of the study sample strati-
fied by gender and CAD status are presented in Table 1
and 2, respectively. The overall prevalence of cardiovas-
cular risk factors including, hypertension, diabetes melli-
tus, cigarette smoking, dyslipidemia, and family history
of CAD were high. The women had a greater prevalence
of hypertension, diabetes mellitus, and dyslipidemia as
compared to men but cigarette smoking and opium ad-
diction were much more frequent in men than in
women. There was no significant difference in the preva-
lence of family history of CAD between men and women
(Table 1). As seen in Table 2, the prevalence of diabetes,
family history of CAD, hyperlipidemia, and cigarette
smoking as well as hypertension and opium addiction
were significantly higher in CAD group whereas there
was no statistically significant difference in age, sex, and
BMI between two groups.
Allele and genotype frequencies for the SCARB1
(rs5888) polymorphism in the case and control groups,
separated by sex, are shown in Table 3. There was no
statistically significant difference in the distribution of
rs5888 genotypes between two groups and in men and
women subgroups after stratification by sex. Table 4
shows that no associations were detected between
SCARB1 rs5888 (C > T) genotypes and lipid profile in-
cluding total cholesterol, HDL-C, LDL-C, and triglycer-
ide levels. Even after analyzing data separately for men
or women, the rs5888 SNP in SCARB1 gene was not as-
sociated with lipid profile in the subgroup of men or
women (data not shown).
After applying a multiple logistic regression model
with adjusting for diabetes, hypertension, cigarette
smoking, opium addiction, BMI, and family history of
CAD as well as triglyceride, HDL-C, and LDL-C, rs5888
polymorphism was found to be associated with the pres-
ence of PCAD in total population and in women but not
in men (Table 5). T allele as compared to C allele was
associated with increased odds of PCAD in total popula-
tion (adjusted OR = 1.3, 95 % CI = 1.0 to 1.5; p = 0.020),
Table 1 Baseline characteristics of the study population stratified by sex
All (n = 1051) Men (n = 477) Women (n = 574) P-value*
Age (years) 45.6 ± 6.0 41.0 ± 3.5 49.4 ± 4.9 <0.001
Body mass index (kg/m2) 29.7 ± 5.7 28.1 ± 4.4 31.1 ± 5.3 <0.001
Cigarette smoking <0.001
Current smoker 213 (20.3) 188 (39.4) 25 (4.4)
Ex-smoker 97 (9.2) 82 (17.2) 15 (2.6)
Non-smoker 741 (70.5) 207 (43.4) 534 (93.0)
Opium addiction 99 (9.4) 91 (19.1) 8 (1.4) <0.001
Hypertension 456 (44.3) 126 (26.4) 339 (59.1) <0.001
Diabetes 240 (22.8) 53 (11.1) 187 (32.6) <0.001
Dyslipidemia 673 (64.0) 290 (60.8) 383 (66.7) 0.046
Family history of CAD 357 (34.0) 157 (32.9) 200 (34.8) 0.511
Fasting blood glucose (mg/dl) 116.7 ± 50.1 106.8 ± 41.1 124.8 ± 52.2 <0.001
Triglyceride (mg/dl) 182.8 ± 116.4 193.3 ± 123.1 174.1 ± 109.9 0.008
HDL-cholesterol (mg/dl) 42.2 ± 11.7 38.5 ± 10.5 45.2 ± 11.8 <0.001
LDL-cholesterol (mg/dl) 117.0 ± 40.3 113.4 ± 37.1 119.9 ± 42.5 0.011
Total cholesterol (mg/dl) 186.8 ± 48.6 182.2 ± 47.7 190.6 ± 49.5 0.005
Creatinine (mg/dl) 0.9 ± 0.6 1.0 ± 0.8 0.8 ± 0.4 <0.001
LVEF (%) 53.8 ± 9.0 52.7 ± 9.7 54.7 ± 8.3 <0.001
Data are presented as mean ± SD or n (%)
CAD Coronary artery disease, LVEF left ventricular ejection fraction
*P-values for men vs. women
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and in women (adjusted OR = 1.3, 95 % CI = 1.0 to 1.8;
p = 0.037), but not in men (adjusted OR = 1.2, 95 %
CI = 0.9 to 1.5; p = 0.311). Among total population,
those with TT genotype had 1.7-fold increased ad-
justed odds of PCAD compared to those with CC
genotype (p = 0.013). When data were analyzed separ-
ately for men or women, SCARB1 (rs5888) TT geno-
type as compared to CC genotype was associated
with increased odds of PCAD in women (adjusted
OR = 2.1, 95 % CI = 1.2 to 4.0; p = 0.014), but not in men
(adjusted OR = 1.3, 95 % CI = 0.7 to 2.5; p = 0.336).
Table 6 shows the association between the studied
polymorphism and the severity of CAD with respect to
vessel score and Gensini score. The distribution of vessel
score was statistically similar among different genotypes
(adjusted p = 0.309). Additionally, in total population,
the median and inter-quartile range for Gensini score
was not significantly different among the CC (42, 20 to
65), CT (42, 23 to 75), and TT (37, 20 to 64) genotypes
(adjusted P = 0.540). There was also no significant asso-
ciation between the examined polymorphism and the se-
verity of CAD within men or women subgroups.
Discussion
The importance of SCARB1 in reverse cholesterol trans-
port and atherosclerosis has been previously confirmed
in mouse models [11]. Moreover, recent studies have
demonstrated rs5888 variant within SCARB1 to be
linked with lipid levels and the size of lipoprotein parti-
cles, especially in younger women [23, 24]. However, the
role of this variant in CAD development among humans
is much less investigated [25]. Here we report, for the
first time to our knowledge, that the SNP rs5888 in the
SCARB1 gene is possibly an independent risk factor for
early onset CAD in a cohort of young Iranian patients
undergoing elective coronary angiography. In this study
we focused on young patients with CAD because we
wanted to investigate a cohort of patients who less af-
fected by the age-related confounding factors; this strat-
egy is more likely to detect genetic effects. The logistic
regression model demonstrated that T allele in compari-
son with C allele had 1.3-fold increased risk for PCAD
in whole and in women subgroup. Also, in men, the T
allele showed a 20 % higher risk for CAD compared to
C allele but this did not reach a statistical significance.
Table 3 Genotype and allele frequencies of rs5888 polymorphism in the SCARB1 gene according to CAD status in whole study
group and in subgroups separated by gender
non- CAD patients CAD patients P-value*
All (n = 546) Male (n = 243) Female (n = 303) All (n = 505) Male (n = 234) Female (n = 271) All Male Female
rs5888 (C > T) 0.163 0.781 0.143
CC 195 (35.7) 88 (36.2) 107 (35.3) 162 (32.1) 81 (34.6) 81 (29.9)
CT 281 (51.5) 121 (49.8) 160 (52.8) 259 (51.3) 115 (49.1) 144 (53.1)
TT 70 (12.8) 34 (14.0) 36 (11.9) 84 (16.6) 38 (16.2) 46 (17.0)
CT + TT 351 (64.3) 155 (63.8) 196 (64.7) 343 (67.9) 153 (65.4) 190 (70.9) 0.214 0.715 0.167
Alleles 0.082 0.544 0.070
C 671 (61.4) 297 (61.1) 374 (61.7) 583 (57.7) 277 (59.2) 306 (56.5)
T 421 (38.6) 189 (38.9) 232 (38.3) 427 (42.3) 191 (40.8) 236 (43.5)
*p-values for non-CAD vs. CAD
Data are presented as n (%)
CAD, Coronary artery disease; SCARB1, scavenger receptor class B type 1
Table 2 Baseline characteristics in the study population based






Age (years) 45.6 ± 6.1 45.6 ± 5.9 0.922
Body mass index (Kg/m2) 29.7 ± 4.9 29.7 ± 5.4 0.996
Male sex 243 (44.5) 234 (46.3) 0.551
Diabetes mellitus 74 (13.6) 166 (32.9) <0.001
Hypertension 192 (35.2) 273 (54.1) <0.001
Smoking status 0.001
Current smoker 87 (15.9) 126 (25.0)
Ex-smoker 48 (8.8) 49 (9.7)
Non-smoker 411 (75.3) 330 (65.3)
Family history of CAD 148 (27.1) 209 (41.4) <0.001
Dyslipidemia 315 (57.7) 342 (72.6) <0.001
Triglyceride (mg/dl) 173.4 ± 114.3 193.0 ± 118.0 0.007
HDL-cholesterol (mg/dl) 43.9 ± 11.5 40.2 ± 11.7 <0.001
LDL-cholesterol (mg/dl) 116.4 ± 36.3 117.6 ± 44.2 0.945
Total cholesterol (mg/dl) 186.9 ± 42.8 186.8 ± 54.3 0.996
Fasting blood glucose (mg/dl) 106.1 ± 36.7 128.3 ± 60.2 <0.001
Creatinine (mg/dl) 0.9 ± 0.6 0.9 ± 0.6 0.981
LVEF (%) 55.7 ± 8.0 51.7 ± 9.6 <0.001
Data are presented as mean ± SD or n (%)
CAD Coronary artery disease, LVEF left ventricular ejection fraction
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Table 4 Lipid profile in total population, and in case and control groups according to rs5888 (C > T) genotypes in SCARB1 gene
CC CT TT P value*
All participants (n = 357) (n = 540) (n = 154) –
Triglyceride (mg/dl) 183.6 ± 108.7 179.6 ± 113.7 192.5 ± 140.5 0.572
HDL cholesterol (mg/dl) 41.8 ± 11.6 42.6 ± 12.1 41.4 ± 10.4 0.569
LDL cholesterol (mg/dl) 119.5 ± 40.2 115.9 ± 40.3 114.9 ± 40.4 0.351
Total cholesterol (mg/dl) 188.5 ± 51.1 186.2 ± 47.3 185.1 ± 47.2 0.691
Non-CAD group (n = 195) (n = 281) (n = 70) –
Triglyceride (mg/dl) 175.7 ± 113.2 166.0 ± 99.0 196.4 ± 162.6 0.065
HDL cholesterol (mg/dl) 43.5 ± 12.6 44.3 ± 11.0 43.8 ± 9.5 0.853
LDL cholesterol (mg/dl) 120.6 ± 36.2 113.0 ± 34.6 118.2 ± 41.6 0.054
Total cholesterol (mg/dl) 189.4 ± 44.0 183.8 ± 40.7 191.5 ± 46.6 0.108
CAD group (n = 162) (n = 259) (n = 84) –
Triglyceride (mg/dl) 193.3 ± 102.5 194.2 ± 126.4 189.1 ± 119.4 0.887
HDL cholesterol (mg/dl) 39.7 ± 10.0 40.8 ± 12. 9 39.3 ± 10.7 0.499
LDL cholesterol (mg/dl) 118.2 ± 44.5 119.0 ± 45.4 112.0 ± 39.4 0.470
Total cholesterol (mg/dl) 189.4 ± 58.9 188.8 ± 53.4 179.6 ± 47.5 0.350
*Adjusted for age, sex, cigarette smoking, and body mass index (BMI)
Data are presented as mean ± SD
CAD, Coronary artery disease; SCARB1, scavenger receptor class B type 1
Table 5 Unadjusted and adjusted odds ratios for the effect of rs5888 genotypes on premature coronary artery disease in whole and
in men and women separately
Unadjusted Adjusted*
rs5888 (C > T) Odds ratio (95 % CI) p-value Odds ratio (95 % CI) p-value
All participants 0.164 0.046
CC 1.0 (Ref.) - 1.0 (Ref.) –
CT 1.1 (0.9 to 1.5) 0.448 1.2 (0.9 to 1.6) 0.204
TT 1.4 (1.0 to 2.1) 0.058 1.7 (1.1 to 2.6) 0.013
CT + TT 1.2 (0.9 to 1.5) 0.214 1.3 (1.0 to 1.7) 0.077
Allele T vs. C 1.2 (1.0 to 1.4) 0.082 1.3 (1.0 to 1.5) 0.020
Male sex 0.781 0.583
CC 1.0 (Ref.) – 1.0 (Ref.) –
CT 1.0 (0.7 to 1.5) 0.874 1.2 (0.8 to 1.8) 0.448
TT 1.2 (0.7 to 2.1) 0.491 1.3 (0.7 to 2.5) 0.336
CT + TT 1.1 (0.7 to 1.6) 0.715 1.2 (0.8 to 1.9) 0.348
Allele T vs. C 1.1 (0.8 to 1.4) 0.544 1.2 (0.9 to 1.5) 0.311
Female sex 0.146 0.044
CC 1.0 (Ref.) – 1.0 (Ref.) –
CT 1.2 (0.8 to 1.7) 0.354 1.1 (0.7 to 1.8) 0.551
TT 1.7 (1.0 to 2.9) 0.050 2.1 (1.2 to 4.0) 0.014
CT + TT 1.3 (0.9 to 1.8) 0.167 1.3 (0.9 to 2.0) 0.202
Allele T vs. C 1.2 (1.0 to 1.6) 0.070 1.3 (1.0 to 1.8) 0.037
*Adjusted for diabetes, hypertension, cigarette smoking, opium addiction, BMI, and family history of CAD as well as triglyceride, HDL-C, and LDL-C
CAD, coronary artery disease; BMI, body mass index; CI, confidence interval; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol;
Ref., the reference category
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Among our study population, rs5888 within SCARB1
gene is a common SNP with minor allele frequency
around 40 %. The variant allele of SNP rs5888 (T allele)
frequency was 0.403 in total; 0.423 in case group and
0.386 in reference group. In a cross-sectional health sur-
vey on Lithuanian population, T allele frequency in the
reference and MI groups was 0.362 and 0.400, respect-
ively [18], whereas in Korean subjects the T allelic fre-
quency was 0.330 in control and 0.170 in CAD [16]. In
white population, the prevalence of this variant varies
between 0.400 and 0.600 [13, 23, 26–28]. Among the
participant of the Framingham Offspring Study, wherein
almost all were Caucasian, the frequency of T allele was
0.486 [28], while in Chinese population T allele fre-
quency varies from 0.217 to 0.290 [22, 29]. These studies
suggest that the frequency of rs5888 mutation is different
in various surveys with various sample sizes, in various
geographical regions, and in various ethnic populations.
Our finding that T allele may be a significant, independent
risk factor for CAD is consistent with the results of a re-
cent candidate gene association study on Chinese [14], but
this is in contrast to the other similar studies [15–18]. In a
Tunisian population, Rejab et al. [17] reported that sub-
jects carrying T allele were associated with an almost 41 %
reduced risk of angiographically documented significant
coronary stenosis. Several other studies on Korean, Span-
ish, and Lithuanian patients also suggested that the T allele
was associated with lower CAD risk [15, 16, 18].
Such disparity in study results may be ascribed to
methodological heterogeneity (differences in study de-
signs, sample sizes, definition of the phenotype, and, age
and gender), different genetic background, and differ-
ences in the nature of various populations. For example,
the precise definition of phenotype in studies on CAD
association is of essential importance because individuals
with significant CAD who are clinically silent may be
classified as controls leading to a higher likelihood of
null results. To avoid this potential bias in the current
study, we defined phenotype based on objective angio-
graphic documentation of coronary artery status. Not-
ably, the examined polymorphism (rs5888) is not among
the list of 46 loci that previously described to be robustly
associated with CAD in large-scale genome-wide associ-
ation studies (GWAS) [30, 31]. In the largest GWAS
meta-analysis of CAD undertaken to date, the Coronary
ARtery DIsease Genome wide Replication and Meta-
analysis (CARDIoGRAM) plus The Coronary Artery
Disease (C4D) consortium (CARDIoGRAMplusC4D),
involving European and South Asian descent, 15 new
susceptibility loci were identified [31]. Four of the 30
CAD risk loci previously reported in individuals of Euro-
pean ancestry (CDKN2B-AS1, COL4A2, CXCL12 and
APOE) were detected as independent additional SNPs
not in LD (r2 < 0.5) with the lead SNP, which also reached
genome-wide significance. The additional SNP in the
APOE locus was rs445925 (P = 9.42 × 10−11; r2 = 0.015
with rs207560 in 1000 Genomes Project data) [31]. There
was no trend for higher odds ratios (ORs) in any of the
subgroup analyses; however, one new locus reached
genome-wide significance in males and in young CAD
cases (rs16986953; P = 1.89 × 10−8 and 1.67 × 10−8, re-
spectively), which was located in a gene desert (with near-
est transcript AK097927), 1.3 Mb away from the APOB
gene [31].
Even though several studies having suggested associ-
ation between the genotypes of rs5888 gene polymorph-
ism and various clinical parameters, the causative role of
this variant is still unknown. Indeed, the exon 8 variant
(rs5888) is a common synonymous or silent SNP that does
not encode for a change in amino acid sequence of the
protein product. Although this silent polymorphism was
conventionally believed to be a nonfunctional marker in
linkage disequilibrium with an as-yet-unidentified causal
variant [13, 15, 32], no linkage has been found between
Table 6 The genotypes of rs5888 single nucleotide polymorphism in association with CAD severity
CC (n = 357) CT (n = 540) TT (n = 154) P-value P-value*
Vessel score, n (%) 0.178 0.247
0 195 (54.6) 281 (52.0) 70 (45.3)
1VD 72 (20.2) 117 (21.7) 46 (29.9)
2VD 40 (11.2) 74 (13.7) 22 (14.3)
3VD 50 (14.0) 68 (12.6) 16 (10.4)
Gensini score, median (25th to 75th percentiles), na.
All 42 (20 to 65), 162 42 (23 to 75), 259 37 (20 to 64), 84 0.449 0.572
Males 43 (26 to 77), 81 40 (23 to 67), 115 36 (25 to 61), 38 0.816 0.697
Females 40 (20 to 64), 81 45 (23 to 78), 144 38 (18 to 66), 46 0.233 0.398
0 no coronary lesion, 1VD one-vessel disease, 2VD Two-vessel disease, 3VD three-vessel disease, CAD coronary artery disease, HDL-C high density lipoprotein
cholesterol, LDL-C low density lipoprotein cholesterol
*P-values adjusted for diabetes mellitus, cigarette smoking, opium addiction, hypertension, and family history of CAD as well as body mass index, serum HDL-C,
triglyceride, and LDL-C
aA total number of 505 patients after excluding 546 with normal coronary arteries (Gensini score = 0)
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this SNP and a known functional promoter variant [15].
Also, the promoter variant appears to be extremely rare
(0.020) in white populations [15]. On the other hand, re-
cent accumulating evidence indicates that silent SNPs
could directly influence expression and/or function of
their gene products [33–35]; using in vitro models, Con-
stantineau et al. [12] demonstrated that synonymous
rs5888 variant affected the RNA secondary structure and
conformation of its gene product, SR-BI, and was signifi-
cantly associated with lower SR-BI expression and its
functionality. Hence, SCARB1 rs5888 T allele may possibly
alter SR-BI expression, and in turn, influence risk for de-
velopment of CAD. Moreover, another possible mechan-
ism for this association may be related to some splicing
regulatory role [36].
We found no associations between SCARB1 rs5888
(C > T) genotypes and lipid profile in our studied pa-
tients. In two other studies, the investigators also did
not find such associations, when combined with other
polymorphisms in the SCARB1 gene, the combined ge-
notypes were related to triglyceride and HDL-C in the
women [13, 37]. However, the association between
SCARB1 gene and lipid profile is complex and still de-
bated [18]. Another notable issue is that subgroup ana-
lysis of men and women demonstrated significant
different frequencies of rs5888 variant of SCARB1 gene
exclusively in women. Significant sex-dependent associa-
tions between SCARB1 genetic variations with lipid pro-
file, BMI, and risk of cardiovascular disease have been
previously shown [13, 17, 18, 27, 32]. As noted by Ritsch
et al. [32], this phenomenon may be justified by a likely
interaction between SCARB1 genotype and estrogen-
dependent regulation of SR-BI expression and lipid pa-
rameters or by a possible effect of sex on factors affect-
ing the function of SR-BI; factors such as cholesteryl
gradient within the cells, HDL-C plasma concentration
and composition of its particles, and triglyceride levels
that influence HDL-C metabolism via cholesterol ester
transfer protein.
There are several limitations in the present study that
should be noted. First, because of case-control design, a
selection bias may have been introduced. Second, the
control group is not representative of the general healthy
population, because it is enriched for people with a high
clinical suspicion of having significant CAD, and al-
though coronary stenosis is ruled out, cardiovascular risk
factors can be assumed to be higher in this group as
compared to the general population. Third, although we
tested a relatively large number of patients with PCAD,
our study was under-powered to detect the 1.2-fold ef-
fect size in male subjects with risk allele (T). Fourth, our
results from a single-center may not be generalized to
other ethnic groups; however, our tertiary referral center
receives patients from all over the country with various
ethnic backgrounds. Finally, the lack of ethnicity data in
the present study is a major limitation that might ex-
plain some of the discrepancy with other studies particu-
larly because the population was from various ethnic
backgrounds; therefore, caution needs to be exercised in
drawing conclusions about the impact of the examined
SNP on PCAD.
Conclusion
Using angiographic data and thus refining the pheno-
type, we found that the SNP (rs5888) within SCARB1 is
independently associated with PCAD in whole study
population and in women, but no association was ob-
served in men. However, the statistical power was not
sufficient to detect an association in male subgroup. Fur-
ther studies, particularly in those with PCAD, with larger
sample size in sex subgroups are required to confirm
such association in well-defined ethnic groups. More-
over, because many genes are involved in the develop-
ment of CAD due to dyslipidemia, further investigations
are needed to test the relationship between polymor-
phisms associated with lipid metabolism and the risk of
CAD. In addition, the exact mechanism and biological
basis of possible role of rs5888 variant in pathogenesis of
CAD needs to be explained.
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